[Treatment of patients with stage III non-small cell lung cancer: concurrent high-dose chemotherapy and radiotherapy]. 2008

S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
Universitaire Medisch Centrum Utrecht, afd. Radiotherapie, Q00.118, Heidelberglaan 100, 3584 CX Utrecht. s.y.elsharouni@umcutrecht.nl

The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting ofchemotherapy and radiotherapy. These can be administered sequentially or concurrently. It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses

Related Publications

S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
April 2005, Seminars in oncology,
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
September 2009, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
November 2010, International journal of radiation oncology, biology, physics,
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
November 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
November 2018, International journal of radiation oncology, biology, physics,
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
March 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
August 2014, Radiation oncology (London, England),
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
January 1985, Progress in clinical and biological research,
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
July 2020, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique,
S Y El Sharouni, and J G J V Aerts, and S Senan, and D K M De Ruysscher, and H J M Groen, and M A Paul, and E F Smit, and E J A Vonk, and A F Verhagen, and F M N H Schramel
January 2021, Oncoimmunology,
Copied contents to your clipboard!